An observational, multicentre, open label non interventional programme to assess the long-term safety and efficacy of Somatuline (registered trade mark) Autogel (registered trade mark) in the treatment of neuroendocrine tumours when administered by patients or their partners ("Home Injection Group") or administered by healthcare professionals.

Trial Profile

An observational, multicentre, open label non interventional programme to assess the long-term safety and efficacy of Somatuline (registered trade mark) Autogel (registered trade mark) in the treatment of neuroendocrine tumours when administered by patients or their partners ("Home Injection Group") or administered by healthcare professionals.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Neuroendocrine tumours
  • Focus Adverse reactions
  • Sponsors Ipsen
  • Most Recent Events

    • 06 Dec 2013 Planned number of patients changed from 30 to 25 as reported by Australian New Zealand Clinical Trials Registry record.
    • 06 Dec 2013 Status changed from active, no longer recruiting to completed as reported by Australian New Zealand Clinical Trials Registry record.
    • 06 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top